ClinicalTrials.govrestricted
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Per
ClinicalTrials.gov study NCT00760877. IPD Sharing: Not stated. Countries: 6. Publications: 1.
ShareScore
36/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 12
- Access
- 4
- Reuse readiness
- 0
- Engagement
- 8